ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.
Volatility & Risk
ProMIS Neurosciences has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
Earnings & Valuation
This table compares ProMIS Neurosciences and Bullfrog AI’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ProMIS Neurosciences | $10,000.00 | 3,394.02 | -$13.21 million | ($1.13) | -1.58 |
Bullfrog AI | $65,000.00 | 359.94 | -$5.36 million | ($0.89) | -3.35 |
Institutional & Insider Ownership
50.1% of ProMIS Neurosciences shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 10.3% of ProMIS Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares ProMIS Neurosciences and Bullfrog AI’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
ProMIS Neurosciences | N/A | N/A | -141.23% |
Bullfrog AI | N/A | -134.87% | -111.19% |
Analyst Ratings
This is a breakdown of recent recommendations for ProMIS Neurosciences and Bullfrog AI, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ProMIS Neurosciences | 0 | 0 | 2 | 0 | 3.00 |
Bullfrog AI | 0 | 0 | 0 | 0 | N/A |
ProMIS Neurosciences currently has a consensus price target of $8.00, suggesting a potential upside of 346.93%. Given ProMIS Neurosciences’ higher possible upside, equities analysts clearly believe ProMIS Neurosciences is more favorable than Bullfrog AI.
Summary
ProMIS Neurosciences beats Bullfrog AI on 8 of the 12 factors compared between the two stocks.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.